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Abstract
trans-Ketoconazole was identified and quantified as impurity of cis-ketoconazole, an antifungal compound, by capillary zone
electrophoresis–electrospray–mass spectrometry (CZE–ESI–MS). The chirality of this impurity was demonstrated separating their enantiomers
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dy adding heptakis-(2,3,6-tri-O-methyl)--cyclodextrin to the separation buffer in capillary electrophoresis (CE) with UV detection. However,
S detection was hyphenated to the CE instrument for its identification. As both compounds are diastereomers, they have the same m/z values
nd are needed to be separated prior to the MS identification. A 0.4 M ammonium formate separation buffer at pH 3.0 enabled the separation of
he impurity from cis-ketoconazole. Under these conditions, the optimization of ESI–MS parameters (composition and flow of the sheath–liquid,
rying temperature, drying gas flow, and capillary potential) was carried out to obtain the best MS sensitivity. CZE–ESI–MS optimized conditions
nabled the identification of trans-ketoconazole as impurity of cis-ketoconazole. In addition, the quantitation of this impurity was achieved in
ifferent samples: cis-ketoconazole standard and three different pharmaceutical formulations (two tablets and one syrup) containing this standard.
n all cases, percentages higher than 2.0 were determined for the impurity. According to ICH guidelines, these values required the identification
nd quantitation of any impurity in drug substances and products.
2006 Elsevier B.V. All rights reserved.
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. Introduction
An impurity is defined as any component of a drug product
hat is not the drug substance or an excipient in the drug prod-
ct. Their detection, identification and quantitation are important
spects in the development of new drug substances and products.
he ICH guidelines on impurities (topics Q3A and B in ICH
armonised Tripartite Guideline) define certain thresholds for
he content of impurities above which they should be identified
nd/or quantified. These thresholds have recently been revised
February 2002 and 2003) establishing 0.05–0.1% in new drug
ubstances and 0.1–1.0% in new drug products, depending on the
mount of drug substance administered per day [1–3]. In fact,
∗ Corresponding author. Fax: +34 91 8854971.
E-mail address: mluisa.marina@uah.es (M.L. Marina).
an accurate analytical profile of a drug substance must fulfill
the requirements of regulatory agencies with respect to toxicity
and safety aspects from the initial stage of the development of a
potential drug to the quality control of a marketed pharmaceu-
tical product [4].
Although HPLC coupled with MS is the most used methodol-
ogy for impurity profiling of drugs, the hyphenation of CE with
MS presents a current interest. As indicated in a recent review
[5], CE has emerged as a powerful analytical tool that can pro-
vide useful information on the chemical properties of drugs,
impurities and metabolites [6,7]. One of the main characteris-
tics of CE is its selectivity, which can be modified to achieve
uniquely tailored separations in order to monitor very differ-
ent drugs, impurities and/or metabolites. Often the separation
is different and complementary to classical techniques such as
HPLC [8]. Moreover, the characterization of new synthesized
drugs as well as unknown compounds in drugs (i.e., impuri-
021-9673/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
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ties or metabolites) constitutes a general analytical problem. In
order to improve sensitivity and selectivity while increasing the
information achievable by CE, this technique can be interfaced
with electrospray MS to bring about a very powerful hyphen-
ated technique. This is because the on-line coupling of CE with
electrospray ionization mass spectrometry (ESI–MS) yields a
powerful method [9–12] in which CE offers high separation
efficiency, while ESI–MS allows the determination of an accu-
rate mass for a wide molecular mass range of molecules. CE
can be coupled with different MS analyzers as quadrupole, ion
trap (IT), time of flight (TOF), etc., IT and TOF mass spec-
trometers being very powerful detectors for CE–ESI–MS due to
their sensitivity and speed. In addition, IT can be used for MSn
experiments, and TOF is especially useful due to its high mass
resolution and the possibility of measured mass accuracy in it.
The possibilities of CE–MS for drug analysis have recently
been reviewed [13]. Based on the multiple applications of CE in
this field and the good possibilities demonstrated by CE–MS in
different fields of application, it can be concluded that CE–MS
can be a very useful tool to characterize drugs and investigate
their impurities and/or metabolites [14].
This work is focused on the identification and determination
of ketoconazole impurities. Ketoconazole, which is a chiral
drug used for the treatment of fungal diseases, is clinically
employed as a racemic mixture (1:1 mixture of the two
enantiomers) of the cis configuration [15]. cis-Ketoconazole (1-
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changes from S to R, both compounds being diastereomers (see
Fig. 1). There are three other possible impurities reported by the
European Pharmacopoeia (impurity II: 1-acetyl-4-[4-[[(2R,4R)-
2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-
dioxolan-4-yl]methoxy]phenyl]1,2,3,4-tetrahydropiperazine,
impurity III: 1-acetyl-4-[4-[[(2R,4R)-2-(2,4-dichlorophenyl)-2-
(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-3[4-(4-
acetylpiperazin-1-yl)phenoxy]phenyl]piperazine and impurity
IV: 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-
1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine)
[16]. As cis-ketoconazole is a chiral drug, the use of chiral
conditions are necessary for the separation of their enantiomers.
However, the separation of diastereomers, such as cis- and
trans-ketoconazole, can be performed under achiral conditions
as they have different chemical properties.
Although the determination of ketoconazole in human plasma
has been successfully performed by HPLC–MS [17], the impu-
rities of this antifungal agent have not been identified and quan-
tified until now. With this purpose, in the present work, the main
impurity of cis-ketoconazole was detected and enantiomerically
separated by CE with UV detection, and identified and quantified
by CE–ESI–MS under achiral conditions. ESI–MS parameters
were optimized in order to obtain the maximum sensitivity for
the determination of trans-ketoconazole present as impurity in
ketoconazole standard and in several commercial pharmaceuti-
cal formulations containing cis-ketoconazole as drug substance.
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conazcetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-
-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine)
ossesses two chiral centers with defined configurations, and
he impurity, trans-ketoconazole (1-acetyl-4-[4-[[(2R,4R)-
-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-
ioxolan-4-yl]methoxy]phenyl]piperazine), has the same chiral
onfiguration as cis-ketoconazole except for position 4 which
Fig. 1. Structures of cis-ketoconazole and trans-keto. Experimental
.1. Chemicals
All chemicals were of analytical grade. Formic acid and acetic
cid were supplied from Riedel-Hage¨n (Seelze, Germany).
ole with their empirical formulas and exact masses.
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Twenty-five percent ammonium solution was supplied from
Merck (Darmstadt, Germany). Dimethylsulfoxide (DMSO)
was purchased from Fluka (Buchs, Switzerland). Heptakis-
(2,3,6-tri-O-methyl)--cyclodextrin (TM--CD) from Sigma
(St. Louis, MO, USA) was used as chiral selector. Methanol,
isopropanol, and acetonitrile were purchased from Scharlau
Chemie (Barcelona, Spain). Water used to prepare solutions was
purified through a Milli-Q system from Millipore (Bedford, MA,
USA). cis-Ketoconazole standard (drug substance) was supplied
from Sigma (St. Louis, MO, USA). Different pharmaceutical
formulations (drug products), tablets and syrup, were obtained
from a pharmacy in Guadalajara (Spain).
2.2. Procedures
Buffer solutions were prepared by diluting the appropriate
volume of formic acid with Milli-Q water and adjusting the pH to
3.0 with 25% ammonia solution before completing the volume
with water to get a 0.4 M formate buffer. Finally, background
electrolytes (BGEs) containing the chiral selector were prepared
by dissolving the appropriate amount of the cyclodextrin in the
buffer solution (0.4 M formate at pH 3.0).
The stock standard solution of the investigated compound
(cis-ketoconazole) was prepared by dissolving it in DMSO up
to a final concentration of 2 mg/mL. Eight diluted solutions of
cis-ketoconazole (0.02, 0.04, 0.10, 0.20, 0.50, 1.00, 1.50 and
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ditioned with the BGE for 2 min. The capillary temperature was
15 ◦C and UV detection was performed at 200 nm with a band-
width of 10 nm using a reference wavelength of 350 nm with a
bandwidth of 100 nm, and a response time of 0.1 s. Injections
were made by pressure, 50 mbar for 4 s, and the applied voltage
was 30 kV.
2.4. CE–MS instrument
The analyses were carried out in an HP3D CE instrument
(Agilent Technologies, Palo Alto, CA, USA) equipped with an
on-column DAD for UV detection, and coupled through an
orthogonal electrospray interface (ESI, model G1607A from
Agilent Technologies, Palo Alto, CA, USA) to an ion-trap mass
spectrometer (model 1100 from Agilent Technologies, Palo
Alto, CA, USA) for MS detection. MS control and data analysis
were carried out using the LC/MSD Trap Software 5.2. Uncoated
fused-silica capillaries of 50m I.D. with a UV detection length
of 20 cm and a MS detection length of 80 cm were used. Injec-
tions were made by pressure, 50 mbar for 4 s, and the applied
voltage was 20 kV. In this instrument the capillary was condi-
tioned with the BGE for 4 min between injections.
Electrical contact at the electrospray needle tip was estab-
lished using a sheath–liquid based on isopropanol:water (50:50,
v:v) and delivered at a flow rate of 3.3L/min by a SGE
Syringe, 10 mL, Luer Lock from Supelco (Bellefonte, PA, USA).
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o.00 mg/mL) were used for calibration in the 0.02–2.00 mg/mL
ange. Calibration for the impurity was performed consider-
ng its percentage in the cis-ketoconazole standard. With this
urpose, the five solutions of cis-ketoconazole with the highest
oncentrations (0.20–2.00 mg/mL) were considered.
Sample solutions of pharmaceutical formulations were pre-
ared in a different way depending on the type of formulation.
ablets were weighed and powdered. Then, an amount of the
owder obtained was weighed and dissolved in 10 mL DMSO
o obtain a concentration of about 2 mg/mL in cis-ketoconazole
taking into account the labeled amount of this compound in
he formulation). Likewise, 500L of syrup was diluted in
MSO to obtain a solution with a concentration of approxi-
ately 2 mg/mL. All solutions were stored at 5 ◦C and then
ltered, prior to the use, through 0.45m pore size disposable
ylon filters from Titan (Eatontown, NJ, USA).
.3. CE–UV instrument
An HP3D CE system (Hewlett-Packard, Waldbronn, Ger-
any) equipped with an on-column diode array detector (DAD)
or UV detection was employed in this work. A 3D-CE Chem-
tation software from Agilent Technologies was used for instru-
ent control and data acquisition. Separations were performed
sing uncoated fused-silica capillaries of 50m I.D. and 375m
.D. with a UV detection length of 70 cm and a total length
f 78.5 cm, which were purchased from Composite Metal Ser-
ices (Worcester, England). Before first use, uncoated capillaries
ere conditioned in the following way: a 30 min rinse with 1 M
aOH was followed by a water rinse for other 5 and 60-min with
he buffer solution. Between injections, the capillary was con-he mass spectrometer was operated in the positive ion mode
4.5 kV). The spectrometer was scanned at 250–750 m/z range.
S operating conditions were optimized. The nebulizer pres-
ure and flow and the drying gas temperature were: 2 psi N2,
nd 4 L/min N2 at 250 ◦C.
. Results and discussion
.1. Detection of impurities in cis-ketoconazole by CE–UV
According to the European Pharmacopoeia [16], four impu-
ities are possible in cis-ketoconazole as raw material. In order
o detect the impurities of cis-ketoconazole and to investigate
heir chiral nature, a 0.4 M formate buffer at pH 3.0 was used
ith increasing concentrations of TM--CD as chiral selec-
or. TM--CD was employed as chiral selector because in a
revious work, this neutral -CD was shown to be the best chi-
al selector for the enantiomeric separation of cis-ketoconazole
15], a compound structurally similar to its impurities. Fig. 2
hows the electropherograms obtained for a cis-ketoconazole
tandard solution under the above-mentioned experimental con-
itions. As it can be observed, in absence of the chiral selector
nly a peak was detected, which is well separated from the
ain compound (cis-ketoconazole). Therefore, only a major
mpurity seems to be detected under these conditions. On the
ther hand, it is interesting to observe that this major impu-
ity is a racemic mixture (1:1 mixture of two enantiomers) that
an be separated from the main compound (cis-ketoconazole)
nd enantiomerically resolved in the presence of TM--CD. In
act, baseline resolution of the enantiomers of the impurity was
bserved with TM--CD concentrations higher than 2 mM (see
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Fig. 2. Electropherograms corresponding to a cis-ketoconazole standard solu-
tion (2 mg/mL in DMSO) in 0.4 M formate buffer at pH 3.0 with increas-
ing concentrations of heptakis-(2,3,6-tri-O-methyl)--CD. Experimental con-
ditions: untreated fused-silica capillary, 78.5 cm (70 cm to the detector window)
×50m I.D.; separation temperature, 15 ◦C; applied voltage, 30 kV; injection,
50 mbar × 4 s; detection at 200 ± 5 nm with reference at 350 ± 50 nm. Cis-ket:
cis-ketoconazole.
Fig. 2). Although the enantioresolution increased at a TM--
CD concentration of 5 mM, the first-migrating enantiomer of
the racemic impurity comigrated with the cis-ketoconazole (see
Fig. 2), i.e., the separation between the main compound and
its major impurity was not complete under these conditions. At
10 mM TM--CD only one enantiomer from the racemic impu-
rity was observed (data not shown).
These results indicated that the impurity of cis-ketoconazole
was a chiral substance, which could be separated from
cis-ketoconazole under achiral conditions because the cis-
ketoconazole and its impurity have different electrophoretic
mobilities. However, this impurity could be trans-ketoconazole
(geometrical isomer) or one of the other three chiral impurities
reported by the European Pharmacopoeia [16].
An estimation of the percentage of impurity detected for
cis-ketoconazole was performed by CE with UV detection
under achiral conditions obtaining a value close to 2%. This
value is above the thresholds established by the ICH guide-
lines for impurities that must be identified or qualified for
registered pharmaceuticals for human use [1–3]. As there
were no commercially available standards for the four pos-
sible impurities of cis-ketoconazole, a probable identifica-
tion by CE with UV detection was not possible. There-
fore, CE–ESI–MS was employed for the identification of this
impurity in cis-ketoconazole because the possible impurities
reported in the European Pharmacopoeia [16] have different
masses (trans-ketoconazole of exact mass = 530.1487 g/mol;
impurity II of exact mass = 528.1331 g/mol; impurity III
of exact mass = 720.2481 g/mol and impurity IV of exact
mass = 488.1382 g/mol). In order to obtain a limit of detec-
tion (LOD) as low as possible, the volatile BGE was used
under achiral conditions because the presence of non-volatile
components (e.g., cyclodextrins) in the BGE decreases the sen-
sitivity, increases the background noise and can clog the system
[18–20]. In addition, under achiral conditions, only one peak was
observed for the impurity, providing a better sensitivity than that
obtained for the two peaks observed under chiral conditions.
3.2. Identiﬁcation of cis-ketoconazole impurity by
CE–ESI–MS
Using formate buffer at pH 3.0 as BGE for the separation of
cis-ketoconazole and its impurity in the format of capillary zone
electrophoresis (CZE), several analytical parameters affecting
ESI–MS sensitivity were studied.
Firstly, different sheath–liquid compositions and flows were
tested in order to increase MS signal. Fig. 3a shows the rela-
tive intensity obtained for cis-ketoconazole, calculated from the
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4xtracted ion electropherogram (EIE) at 531 ± 0.5 m/z, for dif-
erent percentages (0–0.5%) of formic acid in isopropanol:water
50:50, v:v). It can be observed that a sheath–liquid composed of
sopropanol:water (50:50, v:v) without formic acid provided the
est relative intensities. This result can be explained considering
hat the high concentration of formic acid in the BGE is probably
nough to obtain a good ionization of the analytes at the inter-
ace and an adequate electrical contact. Other organic solvents
methanol or acetonitrile) and acetic acid (0–0.5%) instead of
ormic acid were also tested but worse relative intensities were
btained in all cases (results not shown).
Next step was to study the influence of the sheath–liquid
ow on the MS relative intensities of cis-ketoconazole when
sopropanol:water (50:50, v:v) was used. From the differ-
nt sheath–liquid flows studied (1.7–6.7L/min), a flow of
.3L/min provided the highest relative intensities although
imilar values were also obtained for flows of 5.0 and 6.7L/min
see Fig. 3b). Under these sheath–liquid conditions, the effect
f several other ESI parameters (drying temperature, sampling
apillary potential and drying gas flow) was investigated. Four
rying temperatures (200, 250, 300 and 350 ◦C) were tested
bserving that 250 ◦C provided the highest relative intensity (see
ig. 3c) although this parameter had little influence. Four differ-
nt potentials were applied in the sampling capillary observing
he best sensitivity for 4.5 kV (see Fig. 3d). Finally, the drying
as flow was then studied testing values of 2, 3, 4, 5 and 6 L/min
btaining the highest relative intensity with 4 L/min (see Fig. 3e).
n addition, although the resolution between cis-ketoconazole
nd its impurity decreased (from 5.4 to 3.9) with the increment
f the drying gas flow a good resolution (4.9) was observed at
L/min.
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Fig. 3. Bar diagrams showing the relative intensity obtained for the peak of cis-ketoconazole in the EIE at 531 ± 0.5 m/z with: (a) different percentages of formic
acid in a sheath–liquid of isopropanol:water (50:50, v:v) with a flow of 3.3L/min using 2 psi for the nebulizer pressure, 350 ◦C and 4 L/min for the drying gas,
and 4.5 kV in the sampling capillary; (b) different flow rates for a sheath–liquid of isopropanol:water (50:50, v:v) using other conditions as (a); (c) different drying
temperatures using other conditions as (b); (d) different potentials in the sampling capillary using a drying temperature of 250 ◦C, and other conditions as (b) and
(e) different drying gas flow rates using other conditions as (d). CE conditions: untreated fused-silica capillary, 80 cm × 50m I.D.; applied voltage, 20 kV; other
conditions as in Fig. 2.
The selected CE–ESI–MS conditions with a scan between
250 and 750 m/z were used to analyze different samples
containing cis-ketoconazole. Namely, one commercial stan-
dard formulation, and three pharmaceutical formulations, two
tablets and one syrup, were analyzed. Mass spectra were
obtained for cis-ketoconazole and its impurity in all sam-
ples observing that these spectra were practically identical
for all samples analyzed (see Fig. 4), i.e., the mass spec-
tra had the same value of m/z for the protonated molecu-
lar ion, and their isotopic distributions had very similar rel-
ative intensities, which are characteristics of molecules with
two chlorine atoms. Among the possible impurities reported
in the European Pharmacopeoiea [16] (impurity I correspond-
ing to trans-ketoconazole of exact mass = 530.1487 g/mol;
impurity II of exact mass = 528.1331 g/mol; impurity III
of exact mass = 720.2481 g/mol and impurity IV of exact
mass = 488.1382 g/mol), only trans-ketoconozale has the same
value of m/z for the protonated molecular ion as cis-
ketoconazole; therefore, the impurity detected for cis-
ketoconazole was identified as the trans-isomer of ketoconazole.
3.3. Quantitation of trans-ketoconazole in cis-ketoconazole
by CE–ESI–MS
Prior to the quantitation of the impurity in the different ana-
lyzed samples, a comparative study on the quantitative capa-
b
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for the impurity, fragmentation of the 531 m/z parent ion was
investigated under MS/MS conditions. However, in compari-
son with that of the parent ion, no intensity improvement was
observed with the fragments, and therefore single MS analysis
was selected for the rest of the experiments. Then, an m/z win-
dow for the EIE between 531.0 and 0.5 m/z and 531.0 + 4.5 m/z
was selected according to the isotopic distribution (from 531 to
535, see Fig. 4) because the highest intensity of ions and the best
signal-to-noise ratio were obtained under these conditions.
The figures of merit obtained for CE–UV and CE–MS are
summarized in Table 1. As it can be seen, CE–UV provides
faster analysis times than CE–MS as could be expected from the
smaller length of the capillary needed for CE–UV detection in
the CE–MS instrument (20 cm versus 80 cm). The other figures
of merit evaluated were linearity, sensitivity and repeatability. As
trans-ketoconazole standard (impurity) was not available, these
parameters were evaluated by injecting the cis-ketoconazole
standard (main compound) in the CE system with UV and MS
detection.
Linearity was established by injecting by triplicate eight solu-
tions of cis-ketoconazole with concentrations ranging from 0.02
to 2.00 mg/mL (see Section 2.2). It was observed that the sig-
nal measured for the main compound by UV and MS detection
correlated linearly along this range of concentrations. The range
of concentrations for the impurity calculated as the main com-
pound concentration multiplied by 0.021 for UV detection and
0
l
i
wilities of CE–UV and CE–MS analysis of ketoconazole was
imultaneously carried out by using the CE–MS instrument,
s this system also allowed UV-detection at 20 cm of the inlet
osition (see Section 2). In order to improve MS sensitivity.024 for MS detection (see the percentage of impurity calcu-
ated for the cis-ketoconazole standard in Table 2) is also shown
n Table 1. In all cases, good correlation coefficients (>0.99)
ere obtained.
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Fig. 4. Extracted ion electropherograms (from 531.0–0.5 to 531.0 + 4.5 m/z) for a cis-ketoconazole standard, a syrup, and two tablets (A and B) showing the mass
spectra for the standard. Resolution values obtained for cis-ketoconazole and its impurity are included in brackets. CE conditions as in Fig. 3. ESI–MS conditions:
positive ion mode, sampling capillary voltage, 4.5 kV; drying gas flow, 4 L/min; drying temperature, 250 ◦C; nebulizer pressure, 2 psi; sheath–liquid, isopropanol:water
(50:50, v:v) at 3.3L/min; mass scan: 250–750 m/z.
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Table 1
Performance parameters for analysis of ketoconazole by CE–UV and CE–ESI–MS
Parameter CE–UV CE–MS
Main compound Impurity Main compound Impurity
Analysis time (min) 4.4 6.8 17.3 19.7
Linearitya
Concentration range (mg/mL) 0.02–2.00 0.0042–0.042 0.02–2.00 0.0048–0.048
Linear equation y = 6.06 + 657.05x y = −5.32 + 1221.30x y = 7.51 × 105 + 8.15 × 107x y = −3.85 × 105+2.54 × 108x
Standard errorsb sa = 6.75 sb = 6.95 sa = 2.41 sb = 93.47 sa = 1.48 × 106 sb = 1.43 × 106 sa = 3.94 × 105 sb = 1.34 × 107
Correlation coefficient (r) 0.9997 0.9913 0.9994 0.9959
Sensitivityc
LOD (mg/L or %)d 0.03 0.3% 0.05 0.2%
LOQ (mg/L or %)d 0.10 1.0% 0.18 0.8%
Repeatability (RSD%)e
Migration time 2.7 2.9 1.1 1.0
Corrected peak area 2.8 11.9 29.6 29.5
a Eight standard solutions were injected by triplicate within the same day.
b Standard errors of the intercept (sa), and of the slope (sb).
c Values calculated from the study of linearity: LOD, 3sa/b, and LOQ, 10sa/b, where sa is the standard error of the intercept, and b is the slope of the calibration
curve [21].
d Values of LOD and LOQ in mg/L for the main compound and in % for the impurity (referred to 2.00 mg/mL of main compound).
e RSD (%) was calculated from five injections within the same day of a ketoconazole standard solution (0.5 mg/mL).
Sensitivity was evaluated by calculating the LOD and limit
of quantitation (LOQ) for the main compound and its impu-
rity. LOD and LOQ calculated by using a signal-to-noise ratio
of 3 and 10, respectively, are reported in Table 1. The main
compound can be detected at 0.03 mg/mL and quantified at
0.10 mg/mL by UV detection. However, with MS detection
slightly higher concentrations can be detected (0.05 mg/mL) and
quantified (0.18 mg/mL). The percentages of impurity that have
been detected and quantified are about 0.3 and 0.9% by UV and
MS detection, respectively.
Repeatability was determined in order to establish the intra-
day variation in migration times and corrected peak areas. The
relative standard deviation expressed in percentage (RSD%) was
calculated from the data obtained for five runs performed on
the same day and obtained by injecting the main compound
at a concentration of 0.5 mg/mL. RSD percentages lower than
2.9% were obtained for migration times when UV detection was
used and lower than 1.1% for MS detection. Nevertheless, RSD
values obtained for corrected peak areas were much worse for
MS detection than for UV detection. Although these values seem
to be very high (see Table 1), similar values have been reported
in other works on CE–MS published recently [22].
Table 2
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Finally, the quantitation of the impurity in the differ-
ent samples analyzed was performed. Table 2 shows the
percentages obtained for the impurity of cis-ketoconazole
(trans-ketoconazole) (calculated as Aimpurity × 100/Atotal, where
Aimpurity corresponds to the corrected peak area of trans-
ketoconazole and Atotal to the total corrected area, i.e., the sum of
the two peak areas corresponding to cis-ketoconazole and trans-
ketoconazole). A 2.1% of the impurity was determined for the
standard of cis-ketoconazole when CE–UV was used, whereas
2.4% of impurity was determined by CE–MS. For the three
pharmaceutical formulations studied, percentages of impurity
ranging from 2.7 to 3.2% were determined with UV detection
and from 3.0 to 4.0% with MS detection. However, the t-test
showed that there were no statistically significant differences
between the values obtained by the two methods at 95.0% con-
fidence level (p-values between 0.052 and 0.78 were obtained).
Due to the fact that percentages of the cis-ketoconazole impu-
rity determined were higher than 2.0% in all cases, the identifica-
tion and quantitation according to the ICH guidelines should be
carried out. This fact shows the high interest of the development
of a CE–ESI–MS method for the identification and quantitation
of cis-ketoconazole impurity in standard samples and pharma-
ceutical formulations successfully performed in this work.
4. Concluding remarks
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oomparison of the percentage of impurity (expressed as average ± standard
eviation) in the different samples determined by CE–UV and CE–ESI–MS
n = 3), and t-test to compare the means of the two methods
ample CE–UV
% impurity
CE–MS
% impurity
t-test
p-value
is-Ketoconazole standard 2.1 ± 0.2 2.4 ± 0.6 0.54
yrup 2.7 ± 0.6 4.0 ± 0.5 0.052
ablet A 3.2 ± 0.3 3.3 ± 0.4 0.78
ablet B 2.5 ± 0.3 3.0 ± 0.1 0.067The impurity of cis-ketoconazole, a chiral antifungal, has
een detected and identified by CZE–ESI–MS using 0.4 M
mmonium formate at pH 3.0 as separation buffer. Under opti-
um CE–MS conditions, trans-ketoconazole could be identi-
ed as the impurity of cis-ketoconazole. As this impurity is a
iastereomer of the antifungal agent studied and has the samem/z
alue, its previous separation by CE is necessary for its unequiv-
cal identification. In addition, the quantitation of this impurity
M. Castro-Puyana et al. / J. Chromatogr. A 1114 (2006) 170–177 177
in different samples (cis-ketoconazole standard and three differ-
ent pharmaceutical formulations: two tablets and one syrup) has
also been achieved. Impurity contents higher than 2.0% were
determined in all cases.
Acknowledgements
Authors thank the Ministry of Science and Technology
(Spain) for the research project BQU2003-03638. Carmen
Garcı´a-Ruiz thanks the Ministry of Science and Technology for
the Ramo´n y Cajal program (RYC-2003-001). Marı´a Castro-
Puyana thanks the University of Alcala´ for her pre-doctoral
grant.
References
[1] International Conference on Harmonization. ICH Harmonized Tripartite
Guidelines. Q3A(R): Impurities in New Drug Substances. Published in
the Federal Register, vol. 68, No. 68, 2003, pp. 6924–6925.
[2] International Conference on Harmonization. ICH Harmonized Tripartite
Guidelines. Q3B(R): Impurities in New Drug Products. Published in the
Federal Register, vol. 68, No. 220, 2003; pp. 64628–64629.
[3] International Conference on Harmonization. ICH Harmonized Tripartite
Guidelines. Quality topics: Q3 Impurity Testing. <http://www.ich.org/
cache/compo/276-254-1.html> [Checked on January 2006].
[4] I. Toro, J.F. Dulsat, J.L. Fa´bregas, J. Claramunt, J. Chromatogr. A 1043
(2004) 303.
[5] T.K. Natishan, J. Liq. Chromatogr. R. T. 28 (2005) 1115.
[6] C.C. Lin, Y.T. Li, S.H. Chen, Electrophoresis 24 (2003) 4106.
[7] W.C. Sung, S.H. Chen, Electrophoresis 22 (2001) 4244.
[8] G. Guetens, G. De Boeck, M.S. Highley, M. Wood, R.A.A. Maes,
A.A.M. Eggermont, A. Hanauske, E.A. de Bruijn, U.R. Tjaden, J. Chro-
matogr. A 976 (2002) 239.
[9] J.C. Severs, R.D. Smith, in: R.B. Cole (Ed.), Electrospray Ionization
Mass Spectrometry, Fundamentals, Instrumentation and Applications,
Wiley, New York, 1997, p. 343.
[10] P. Schmitt-Kopplin, M. Frommberger, Electrophoresis 24 (2003)
3837.
[11] J. Herna´ndez-Borges, C. Neusu¨ß, A. Cifuentes, M. Pelzing, Elec-
trophoresis 25 (2004) 2257.
[12] C. Simo´, C. Barbas, A. Cifuentes, Electrophoresis 26 (2005) 1306.
[13] W.F. Smyth, Electrophoresis 26 (2005) 1334.
[14] W.F. Smyth, P. Brooks, Electrophoresis 25 (2004) 1413.
[15] M. Castro-Puyana, A.L. Crego, M.L. Marina, Electrophoresis 26 (2005)
3960.
[16] European Pharmacopoeia, 4th ed., 2002.
[17] Y.L. Chen, L. Felder, X. Jiang, W. Naidong, J. Chromatogr. B 774
(2002) 67.
[18] G.A. Ross, LC-GC Eur. 1 (2001) 2.
[19] R.D. Smith, J.H. Wahl, D.R. Goodlett, S.A. Hofstadler, Anal. Chem. 65
(1993) 574.
[20] W.M.A. Niessen, U.R. Tjaden, J. Van der Greef, J. Chromatogr. 636
(1993) 3.
[21] L.L.A. Currie, Pure Appl. Chem. 67 (1995) 1699.
[22] M. Arias, C. Simo´, L.T. Ortiz, M. de los Mozos-Pascual, C. Barbas, A.
Cifuentes, Electrophoresis 26 (2005) 2351.
